In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates

BACKGROUND AND OBJECTIVES TNP-2092 is a novel dual-action lead compound consisting of rifamycin SV and 4H-4-oxo-quinolizine pharmacophores, with a broad spectrum of antibacterial activities. This compound is currently in the early stage of clinical development for Helicobacter pylori inf...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Ben Wang, Qiaoyun Zhao, Wenzhu Yin, Ying Yuan, Xiaomei Wang, You-hua Wang, Hui Wang, Wen Ye, Shuping Chen, Hai-long Guo, Yong Xie
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2018-07-01
Schriftenreihe:	Swiss Medical Weekly
Schlagworte:	Helicobacter pylori drug resistant
Online-Zugang:	https://www.smw.ch/index.php/smw/article/view/2501
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!